FIA
CRNX icon

FNY Investment Advisers’s Crinetics Pharmaceuticals CRNX Stock Holding History

FNY Investment Advisers’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-2,000
Closed -$57K – 745
2018
Q3 		$57K Buy
+2,000
New +$59.4K 0.01% 349

Other funds holding CRNX

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FNY Investment Advisers's CRNX Position: Q4 2018 in Review

FNY Investment Advisers sold out of Crinetics Pharmaceuticals (CRNX) in Q4 2018, closing a stake of 2,000 shares — an estimated $57K sold.

FNY Investment Advisers first reported a position in CRNX in Q3 2018 and held it in 1 quarter. The position peaked at $57K in Q3 2018. 50 funds tracked by Wall St. Rank hold CRNX as of Q4 2018.

  • FNY Investment Advisers reported no remaining Crinetics Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • FNY Investment Advisers sold 2,000 Crinetics Pharmaceuticals shares in Q4 2018, an estimated $57K.
  • FNY Investment Advisers first reported a position in Crinetics Pharmaceuticals in Q3 2018 and held it in 1 quarter.
  • FNY Investment Advisers's Crinetics Pharmaceuticals position peaked at $57K in Q3 2018.
  • 50 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q4 2018.

Based on FNY Investment Advisers's 13F filing for Q4 2018, filed 22 Jan 2019.